High-Risk Large B-Cell Lymphoma and the ZUMA-12 study
ZUMA-12 is a single-arm phase II trial in which 42 patients received axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma
ZUMA-12 is a single-arm phase II trial in which 42 patients received axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma
Kite, A Gilead company, have announced that its CAR-T cell therapy, axicabtagene ciloleucel (Yescarta®), is now publicly funded and available for the treatment of patients with relapsed or refractory CD-19 […]
Patients with certain blood cancers will benefit from recent approvals for CAR-T therapy to be manufactured in Australia for the first time within the Peter MacCallum Cancer Centre. Australian patients […]
https://pubmed.ncbi.nlm.nih.gov/32897885/ Authors: Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA et al. J Clin Invest 2020;130(12):6656-6667.
https://pubmed.ncbi.nlm.nih.gov/33098996/ Authors: Hiltbrunner S, Bristchgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P et al. Ann Oncol 2021;32(1):120-121
https://pubmed.ncbi.nlm.nih.gov/33230103/ Authors: An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q et al. Nat Commun 2020;11(1):5928
CARs have produced remarkable outcomes in relapsed and refractory B-cell malignancies. However, replicating this success in acute myeloid leukaemia (AML) is not straightforward.
https://pubmed.ncbi.nlm.nih.gov/32888407/ Authors: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al. Lancet 2020;396(10254):839-852.
https://pubmed.ncbi.nlm.nih.gov/32448949/ Authors: Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K et al. Int J Clin Oncol 2020;25(9):1736-1743.
https://pubmed.ncbi.nlm.nih.gov/32744738/ Authors: Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A et al. Am J Hematol 2020;95(11):1324-1333.